Medical Pharmacology Chapter 35  Antibacterial Drugs

Section Table of Contents

Site Table of Contents

Previous Page

Next Page

  • The Aminopenicillins:  Ampicillin and Amoxicillin

    • Some Therapeutic Uses

      • Meningitis and CNS Infections

        Meningitis Audio Overview
        •  

          Meninges of the CNS

        •  

          Neisseria meningitidis

          • "This micrograph depicts the presence of aerobic Gram-negative Neisseria meningitidis diplococcal bacteria; Mag. 1150X. Meningococcal disease is an infection caused by the bacterium called N. meningitidis or meningococcus. The meningococcus lives in the throat of 5-10% of healthy people. Rarely, it can cause serious illness such as meningitis or blood infection."

          • Attribution

         

        • Ampicillin is an important antibiotic in the treatment of certain forms of bacterial meningitis.

          • While third-generation cephalosporins (e.g. ceftriaxone or cefotaxime) are the mainstay for most community-acquired bacterial meningitis (covering S. pneumoniae, N. meningitidis), there is one prominent pathogen that cephalosporins do not cover: Listeria monocytogenes.3 

            • Listeria primarily causes meningitis in neonates, the elderly (>50 years), pregnant women, and immunocompromised hosts, and it is intrinsically resistant to cephalosporins.2

            • Ampicillin (or penicillin G) is the drug of choice for Listeria infections, including meningitis.2

            •  WHO guidelines for bacterial meningitis recommend adding ampicillin to the empiric regimen whenever Listeria is a consideration.4    Often an aminoglycoside (gentamicin) is added to ampicillin for Listeria meningitis in severe cases to achieve synergy, though definitive evidence of improved outcomes with gentamicin is limited.2   Gentamicin is often part of initial therapy (along with e.g. ampicillin) for Listeria.2

            • An alternative for Listeria coverage, for example in the presence of penicillin allergy, is trimethoprim-sulfamethoxazole, as it penetrates the CSF and is listericidal. 

              • Meropenem is another alternative.2

          • Aside from Listeria, ampicillin is active against many other meningeal pathogens.

            • Ampicillin covers Group B Streptococcus (Streptococcus agalactiae), a cause of neonatal meningitis, and is often included (with gentamicin) in empiric neonatal meningitis regimens.5 

              • It also covers Neisseria meningitidis, Escherichia coli, non-beta-lactamase H. influenzae.

                • Penicillin or ampicillin can be used to treat susceptible N. meningitidis meningitis.

              • Ampicillin’s ability to penetrate the CSF is good when the meninges are inflamed5, achieving bactericidal concentrations.

                • Because up to ~30% of H. influenzae strains produce beta-lactamase and because penicillin-resistant pneumococci exist, the standard of care in meningitis is to use ceftriaxone (which covers those) plus vancomycin (for resistant pneumococci), and add ampicillin specifically for Listeria coverage when indicated.2

                • In summary, ampicillin is indispensable for Listeria meningitis and would be included in empiric therapy for meningitis in neonates and older adults.2

                  • Ampicillin penetrates well into brain abscesses and cerebrospinal fluid with inflammation, so it may be used for Listeria brain abscess.6 

      • Endocarditis and Enterococcal Infections

        • Enterococcus (E. Faecalis & E. Faecium)
        • Ampicillin is useful in treating enterococcal infections, including endocarditis and enterococcal bacteremia.8,9 

          • Enterococcus faecalis is a Gram-positive coccus inherently resistant to many antibiotics, but it is usually susceptible to ampicillin, unlike E. faecium, which is often ampicillin-resistant.6,7 

        • Ampicillin is may be bacteriostatic by itself against enterococci in vitro , meaning it inhibits growth but often does not rapidly kill the organisms.10 

          • Serious enterococcal infections like endocarditis (infection of heart valves), bacteriostatic activity is not sufficient thus necessitating bactericidal combinations.

            • Standard therapy for Enterococcus faecalis endocarditis is ampicillin combined with an aminoglycoside (gentamicin) or cephalosporin (ceftriaxone) to achieve bactericidal synergy.11 

              • Ampicillin damages the cell wall and may facilitate gentamicin entry into the bacterial cell, together proeducing a bactericidal effect.12 

            • Clinical guidelines (American Heart Association and IDSA) traditionally recommended ampicillin (or aqueous penicillin G) plus gentamicin for enterococcal endocarditis for 4–6 weeks.13

              • This regimen cures most E. faecalis endocarditis, but gentamicin can cause nephrotoxicity and ototoxicity, and some enterococcal strains have high-level aminoglycoside resistance (HLAR).

            • Other current clinical guidelines suggest combining ampicillin with other agents e.g. ceftriaxone or daptomycin etc.14

        • Enterococcal bacteremia management begins with identifying and controlling the source, which is most often the urinary tract, an intra-abdominal process, or an infected intravascular catheter.15

          • For ampicillin-susceptible strains, high-dose IV ampicillin is a treatment of choice.16 

            • A critical step in management is to rule out endocarditis, particularly in cases of E. faecalis bacteremia, which often requires echocardiography.17

            • For uncomplicated bacteremia where the source is controlled (e.g., catheter removal), a treatment duration of 7 to 14 days is generally sufficient.18

    • Some Adverse Reactions

      • Allergic reactions

        • Amoxicillin and ampicillin can cause hypersensitivity reactions in susceptible individuals.

          • These reacttopms range from mild rashes to severe anaphylaxis.

            • Penicillin allergy is the most important contraindication,

              • Any patient with a history of penicillin anaphylaxis should not receive aminopenicillins, due to risk of IgE-mediated reaction.19  Typical allergic manifestations include urticaria (hives), angioedema, pruritus, and wheezing or anaphylactic shock in severe cases.19 

                • Aminopenicillins can also cause delayed hypersensitivity rashes that are not IgE-mediated.20

                  • An example is ampicillin/amoxicillin rash in patients with viral infections: when ampicillin or amoxicillin is administered during acute Epstein-Barr virus (mononucleosis) infection, a high proportion of patients develop a non-allergic generalized maculopapular rash.21

                    • A case report suggests that aminopenicillins may trigger characteristic rashes after the onset of mononucleosis, even when given during the infections latent phase.22 

                  • This “ampicillin rash” is immunologically distinct from a true penicillin allergy and does not preclude future use of penicillins, but it is a well-known reaction.23

                  • Amoxicillin/ampicillin are generally avoided in patients with mononucleosis as these drugs may induce a pruritic erythematous maculopapular skin rash.24 

        • Gastrointestinal Effects

          • Aminopenicillins are associated with GI side effects.

            • Adverse effects include diarrhea, nausea, and vomiting.

              • Ampicillin frequently causes diarrhea when given orally.25

                • Amoxicillin and ampicillin can cause changes in the gut microbiome that lead to superinfections: for instance, overgrowth of Candida yeasts (oral thrush or vaginal yeast infection) or Clostridioides difficile colitis.26 

                • Antibiotic-associated diarrhea can occur with aminopenicillins, and in some cases severe C. difficile–associated diarrhea (pseudomembranous colitis) has been reported.19,26

September, 2025

Section Table of Contents

Site Table of Contents

 
References
  1. MacDougall C Chapter 58 Cell Envelope Disruptors: In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton LL Knollman BC eds) McGraw HIil LLC (2023).

  2. Shoham S Listeria Monocytogenes. Johns Hopkins ABX Guide. https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540318/all/Listeria_Monocytogenes#

  3. Vasudeva S Meningitis Treatment & Management. Medscape. (Updated: February 6, 2025). https://emedicine.medscape.com/article/232915-treatment

  4. WHO Guidelines on meningitis in diagnosis, treatment and care. World Health Organization. 2025 https://iris.who.int/bitstream/handle/10665/381006/9789240108042-eng.pdf?sequence=1

  5. Peechakara B Basit H Gupta Ampicillin. StatPearls. National Library of Medicine. (Last update: August 28, 2023). https://www.ncbi.nlm.nih.gov/books/NBK519569/#

  6. Herra-Hidalgo L Lomas-Cabezas J Lopez-Corrtes L Luque-Marquez R Lopez-Cortez L Martinez-Marcxos F de la Torre-Lima J Plata-Ciezar A Hidalgo-Tenorio C LGarcia-Lopez M Vinuesa D Gutierrez-Valencia A Gil-Navarro V De  Alarcon A On behalf of the Cardiovascular Infectious Study Group of the Andalusian Society of Infectious Diseases. Ampicillin Plus Ceftriaxone Combine Therapy for Enterococcus faecalis Infective Endocarditis in OPAT (Outpatient Parenteral Antibiotic Treatment) J Clin Med. 2021 December 21;(11(1): 7. https://pmc.ncbi.nlm.nih.gov/articles/PMC8745305/

  7. Faury H Le Guen R Dmontant V Rodriguez C Souhail B Galy A Jolivet S Lepeule R Decousser J Fihman V Woerther P-L Royer G Ampicillin-susceptible Enterococcus faecium infections: clinical features, causal clades, and contributions of MALDI-TOF to early detection. [MALDI-TOF: Matrix -assisted laser desorption/ionization time-of-flight mass spectrometry]Microbiology Spectrum. Volume 11, Number 5. 25 September 2023. https://journals.asm.org/doi/10.1128/spectrum.04545-22

  8. Kristich C Rice  L Arias C Enterococcal Infection-Treatment and Antibiotic Resistance. Enterococci F:rom Commensals to Leading Causes of Drug Resistant Infection. (Gilmore M Clewell D Ike Y et al, eds. Boston: Massachusetts By an Year Infirmary. (February 6, 2014). https://www.ncbi.nlm.nih.gov/books/NBK190420/

  9. Marino A Munnafo A Zagami A Ceccarelli M De Mauro R Cantarella G Bernardini R Nunnar iG Cacopardo B Ampicillin Plus Ceftriaxone Regimen against Enterococcus faecalis endocarditis: A Literature Review. J Clin Med. 2021 October 6;10(19). https://pmc.ncbi.nlm.nih.gov/articles/PMC8509562/

  10. Werth B Shireman L Pharmacodynamics of Ceftaroline plus Ampicillin against Enterococcus faecalis in an In Vitro Pharmacokinetic/Pharmacodynamic model of Simulated Endocardial Vegetations. Antimicrobial Agents and Chemotherapy. Volume 61, number 4. 24 March 2017.https://journals.asm.org/doi/10.1128/aac.02235-16

  11. Tackling G Lala V Endocarditis antibiotic regimens. StatPearls. National Library of Medicine. (Last update: April 10, 2023). https://www.ncbi.nlm.nih.gov/books/NBK542162/

  12. Beganovic M Luther M Rice L Arias C Rybak M LaPlante K A Review of Combination Antimicrobial Therapy for Enterococcus faecalis Bloodstream Infections and Infective Endocarditis. Clinical Infectious Diseases, volume 67, Issue 2, 15 July 2018; 303-309. https://academic.oup.com/cid/article/67/2/303/4829420

  13. Peechakara B Basit H Gupta M Ampicillin. StatPearls. National Library of medicine. (Last update: August 28, 2023). https://www.ncbi.nlm.nih.gov/books/NBK519569/#

  14. Herra-Hidalgo L Fernandez-Rubio B Luque-Marquez R Lopez-Cortes L Gil-Navarro M de Alarcon A Treatment of Enterococcus faecalis Infective Endocarditis: A Continuing Challenge. Antibiotics (Basel). 2023 April 4;12(4):704. https://pmc.ncbi.nlm.nih.gov/articles/PMC10135260/

  15. Said M Tirhani E Lesho E Enterococcus Infections. StatPearls. National Library of Medicine. (Last update. Every 12, 2024). https://www.ncbi.nlm.nih.gov/books/NBK567759/

  16. Fraser S Enterococcal Infections Treatment & Management. Medscape (updated: July 15, 2024). https://emedicine.medscape.com/article/216993-treatment

  17. Seby R Kim C Khreis M Khreis K Enterococcus faecalis -induced infective endocarditis: an unusual source of infection and a rare clinical presentation.J Int Med Res. 2022 July 28;50(7). https://pmc.ncbi.nlm.nih.gov/articles/PMC9340997/

  18. Maldonado N Rosso-Fernandez C Portillo-Calderon I Borreguero I Tristan-Clavijo E Palacios-Baena Z Salamanca E Fernandez-Cuenca F De-Cueto M Stolz-Larrieu E Rodriguez-Bano J Lopez-Cortez L Randomized, open-labile non-inferiority clinical trial on the efficacy and safety of a 7-day vs 14-day course of antibiotic treatment for uncomplicated enterococcal bacteremia: the INTENSE trial protocol.BMJ Open Volume 13, Issue 9 2023. https://bmjopen.bmj.com/content/13/9/e075699

  19. Ampicillin https://en.wikipedia.org/wiki/Ampicillin#

  20. Schiavino D Nucera E De Pasquale T Roncallo C Pollastrini E Lomardo C Giuliani L Larocca L Buonomo A Patriarca G Delayed allergy to aminopenicillins: clinical and immunological findings. Int J Imunopathol Pharmacol. 2006 October-December;19(4): 831-840. https://pubmed.ncbi.nlm.nih.gov/17166404/

  21. Fox R Ghedia R Nash R Amoxicillin-associated ration glandular fever. (Mononucleosis) BMJ Case Rep. 2015 September 14;2015. https://pmc.ncbi.nlm.nih.gov/articles/PMC4577711/

  22. Watanabe H Sainokami S Adachi N Takizawa K Kanda S Amoxicillin-Triggered Rash in Latent Epstein-Barr Virus Infection: A Case of Kawasaki Disease Mimickry in a Seven-Year-Old Girl. Cureus. 2025 January 24;17(1). https://pmc.ncbi.nlm.nih.gov/articles/PMC11848226/

  23. Bhattacharya S The Facts About Penicillin Allergy: A Review. J Adv Pharm Technol Res. 2010 January-March;1(1): 11-17. https://pmc.ncbi.nlm.nih.gov/articles/PMC3255391/

  24. Ampicillin Disease Interactions Drugs.com https://www.drugs.com/disease-interactions/ampicillin.html

  25. Ampicillin Side Effects (updated Jan 23, 2025). Drugs.com https://www.drugs.com/sfx/ampicillin-side-effects.html

  26. Akhavan B Khanna N Vijhani P Amoxicillin. StatPearls. National Library of Medicine. (Last update: November 17, 2023). https://www.ncbi.nlm.nih.gov/books/NBK482250/

 

This Web-based pharmacology and disease-based integrated teaching site is based on reference materials, that are believed reliable and consistent with standards accepted at the time of development. Possibility of human error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete. Users should confirm the information contained herein with other sources. This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site. Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals. Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.  Advertisements that appear on this site are not reviewed for content accuracy and it is the responsibility of users of this website to make individual assessments concerning this information.  Medical or other information  thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.